Systemic therapy for malignancy in patients on antiretroviral medications
- Michelle A Rudek, PharmD, PhD
Michelle A Rudek, PharmD, PhD
- Associate Professor of Oncology
- Director of the Analytical Pharmacology Core Lab
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Richard F Ambinder, MD, PhD
Richard F Ambinder, MD, PhD
- James B Murphy Professor of Oncology
- Johns Hopkins School of Medicine
- Charles W Flexner, MD
Charles W Flexner, MD
- Professor of Medicine, Pharmacology and Molecular Sciences, and International Health
- Johns Hopkins University School of Medicine and Bloomberg School of Public Health
- John F Deeken, MD
John F Deeken, MD
- Associate Professor
- Virginia Commonwealth University
- Associate Director for Medical Oncology and Clinical Research
- Inova Comprehensive Cancer and Research Institute
The morbidity and mortality associated with human immunodeficiency virus (HIV) has been substantially decreased with the use of potent antiretroviral therapy (ART). For most HIV-infected individuals treated with potent ART, the acquired immunodeficiency syndrome (AIDS) has been transformed into a chronic disease. (See "The impact of antiretroviral therapy on morbidity and mortality of HIV infection in resource-limited settings" and "When to initiate antiretroviral therapy in HIV-infected patients", section on 'Benefits of antiretroviral therapy'.)
With increased longevity, both AIDS-related and non-AIDS-related malignancies have become an important cause of illness among individuals infected with HIV. The specific malignancies associated with an increased incidence in people infected with HIV are reviewed elsewhere. (See "HIV infection and malignancy: Epidemiology and pathogenesis" and "HIV infection and malignancy: Management considerations".)
PRIORITIZATION BETWEEN CANCER AND HIV TREATMENT
Systemic therapy of malignancy in patients infected with HIV presents difficult challenges because of the overlapping toxicities and potential drug-drug interactions between anticancer and antiretroviral agents. Avoiding unexpected toxicity or lack of therapeutic effectiveness requires a close collaboration between the infectious disease expert managing the antiretroviral therapy (ART) for HIV infection and the medical oncologist treating the cancer.
Optimal management of HIV infection generally utilizes continuous treatment with multiple antiretroviral agents to minimize the risk of developing resistant HIV strains, opportunistic infection, and/or death. However, advanced malignancy can pose an immediate threat to health and survival, and this may require that antineoplastic treatment take priority over ART [1,2]. As the agents utilized to treat both cancer and HIV infection evolve, it may be possible to maintain the optimal regimens to maximize treatment benefit for the HIV infection and malignancy. In the interim, management of regimens may involve alteration of doses to maintain therapeutic efficacy and minimize toxicity or modification of the selection of ART or anticancer drugs to avoid the interactions.
There are significant risks associated with stopping ART, as was demonstrated when intermittent ART was found to be inferior to constant dosing. Dose modifications or the use of alternative medications for either the ART or the anticancer medications may be required to balance the competing treatment needs. Newer generation antiretroviral drugs (eg, dolutegravir, raltegravir, maraviroc) have a decreased risk of drug-drug interactions with anticancer agents and may be reasonable alternatives. (See 'Management' below.)To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:
- Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren J, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283.
- SMART Study Group, El-Sadr WM, Grund B, et al. Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. Ann Intern Med 2008; 149:289.
- Moyle GJ, Sadler M. Peripheral neuropathy with nucleoside antiretrovirals: risk factors, incidence and management. Drug Saf 1998; 19:481.
- GlaxoSmithKline. RETROVIR (zidovudine) Tablets, Capsules, and Syrup Package Insert: Prescribing Information. 2010.
- Bower M, McCall-Peat N, Ryan N, et al. Protease inhibitors potentiate chemotherapy-induced neutropenia. Blood 2004; 104:2943.
- Cianfrocca M, Lee S, Von Roenn J, et al. Pilot study evaluating the interaction between paclitaxel and protease inhibitors in patients with human immunodeficiency virus-associated Kaposi's sarcoma: an Eastern Cooperative Oncology Group (ECOG) and AIDS Malignancy Consortium (AMC) trial. Cancer Chemother Pharmacol 2011; 68:827.
- Rudek MA, Moore PC, Mitsuyasu RT, et al. A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061. Cancer 2014; 120:1194.
- Walker UA, Bäuerle J, Laguno M, et al. Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine. Hepatology 2004; 39:311.
- Hughes CA, Robinson L, Tseng A, MacArthur RD. New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir. Expert Opin Pharmacother 2009; 10:2445.
- Lankisch TO, Moebius U, Wehmeier M, et al. Gilbert's disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype. Hepatology 2006; 44:1324.
- Rotger M, Taffe P, Bleiber G, et al. Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J Infect Dis 2005; 192:1381.
- Strassburg CP. Pharmacogenetics of Gilbert's syndrome. Pharmacogenomics 2008; 9:703.
- Ly T, Ruiz ME. Prolonged QT interval and torsades de pointes associated with atazanavir therapy. Clin Infect Dis 2007; 44:e67.
- Abbott. KALETRA® (lopinavir/ritonavir) tablets and oral solution Package Insert (http://rxabbott.com/pdf/kaletratabpi.pdf). North Chicago, IL 2010.
- Genetech USA, I. INVIRASE® (saquinavir mesylate) Capsules and Tablets Package Insert (http://www.gene.com/gene/products/information/invirase/pdf/pi.pdf). South San Francisco, CA 2010.
- Janssen Therapeutics, Division of Janssen Products, LP. EDURANT (rilpivirine) tablets prescribing information. Titusville, NJ August 2015. http://www.edurant.com/shared/prescribing-information-edurant.pdf (Accessed on April 11, 2017).
- Mounier N, Katlama C, Costagliola D, et al. Drug interactions between antineoplastic and antiretroviral therapies: Implications and management for clinical practice. Crit Rev Oncol Hematol 2009; 72:10.
- Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 2010; 49:493.
- National Cancer Institute Cancer Therapy Evaluation Program: Guidelines regarding the inclusion of cancer survivors and HIV-positive individuals on clinical trials, Bethesda, MD 2006.
- Little RF, Pittaluga S, Grant N, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood 2003; 101:4653.
- Sparano JA, Lee S, Chen MG, et al. Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Trial (E1494). J Clin Oncol 2004; 22:1491.